Gene Therapy: Page 28
-
Novartis looking earlier for deals as biotech valuations stay high
The Swiss pharma, which bought AveXis and its gene therapy Zolgensma last year, expects to spend about $10 billion a year on acquisitions.
By Ned Pagliarulo • May 23, 2019 -
Yujin Kim/BioPharma Dive
Could Novartis' gene therapy have more than one price?
Indication-based pricing may be possible for less severe patients, who would receive a smaller dose. Lower manufacturing costs would lessen the blow to Novartis too.
By Jonathan Gardner • May 23, 2019 -
Explore the Trendline➔
Getty Images
TrendlineGene Therapy
Rapid scientific advances have put the gene therapy field at the forefront of biomedical research. But, as recent setbacks have shown, researchers and drugmakers still face major challenges.
By BioPharma Dive staff -
UniQure snags patents on Huntington's gene therapy as it preps for the clinic
The biotech aims to start a Phase 1/2 study in the second half of 2019 for the experimental gene therapy.
By Andrew Dunn • May 22, 2019 -
Bayer pumping $150M more into biologics
A new facility will focus on large-molecule therapies for oncology, cardiology and additional specialty care areas.
By Jacob Bell • May 13, 2019 -
Nearing gene therapy launch, Bluebird cautions a slower start
Zynteglo, Bluebird's experimental therapy for beta-thalassemia, could soon be cleared in Europe. Reworking payment models to adjust will take time.
By Ned Pagliarulo • May 9, 2019 -
Roche risdiplam data heats up SMA rivalry with Novartis
The oral agent looks like it could give gene therapy Zolgensma a run for its money.
By Jonathan Gardner • May 7, 2019 -
Novartis makes final Zolgensma pitch before FDA decision
The most severe spinal muscular atrophy patients showed sustained benefit, the company said in a data update at a neurology meeting.
By Jonathan Gardner • May 6, 2019 -
Gilead's first move under new chief is to untether Kite
Kite is now its own unit within the big biotech, a move that newly minted CEO Daniel O'Day says will improve cell therapy development.
By Jacob Bell • May 3, 2019 -
Yujin Kim/BioPharma Dive
At gene therapy meeting, insurance execs grapple with expected cost
As more gene therapies move closer to market, questions around pricing and reimbursement have taken on greater urgency for regulators, payers and drugmakers.
By Ned Pagliarulo • April 30, 2019 -
Roche's takeout of Spark not working like a Swiss watch
Antitrust review drags on, forcing the two parties to withdraw and refile paperwork and extend the tender offer by another month.
By Jonathan Gardner • April 26, 2019 -
Medicare proposes raising CAR-T pay, but reimbursement solution years away
As new technologies nip at CAR-T's heels, CMS could take three years to gin up a separate reimbursement category for Novartis' Kymriah and Gilead's Yescarta.
By Jonathan Gardner • April 24, 2019 -
Novartis chief defends cell, gene therapy push
CEO Vas Narasimhan has bet heavily on complex medicines, but the pharma's first quarter earnings show that plan is a work in progress.
By Ned Pagliarulo • April 24, 2019 -
'Bubble boy' gene therapy results shoot Mustang Bio's stock up 200%
Following the clinical success, BioPharma Dive spoke with Mustang's CEO on the manufacturing hurdles still standing in the therapy's way.
By Andrew Dunn • April 18, 2019 -
'This is a cure.' St. Jude's gene therapy succeeds in 'bubble boy' disease study
Treatment has rebuilt the immune systems of 10 boys with the life-threatening condition, allowing them to live normal lives so far.
By Andrew Dunn • April 17, 2019 -
Sarepta may have seen off another rival in Wave
Toxicity observed with Wave's DMD drug raises questions over whether the biotech can find a safe and effective dose.
By Jonathan Gardner • April 17, 2019 -
With FDA decision near, Novartis bolsters SMA gene therapy case
Zolgensma could be approved by the FDA within weeks. Fresh clinical data give further evidence of the therapy's benefit, although reports of two deaths invite questions.
By Ned Pagliarulo • April 16, 2019 -
Catalent to buy Paragon for $1.2B as gene therapy demand grows
The deal follows close on the heels of Thermo Fisher's buy of Brammer Bio, a peer of Paragon in making the viral vectors needed for gene therapy.
By Jacob Bell • April 15, 2019 -
Audentes lays down marker in muscular dystrophy
In a challenge to Sarepta, Solid and Pfizer, a new gene therapy approach aims to deliver a more functional muscle-repairing protein to DMD patients.
By Jonathan Gardner • April 8, 2019 -
Yujin Kim/BioPharma Dive
What to look for after Zolgensma's launch
An ICER report provides clues on how payers will hedge their reimbursement bets for a likely million-dollar neuromuscular-disease treatment.
By Jonathan Gardner • April 4, 2019 -
FDA warns of potential violations at 21 stem cell clinics, manufacturers
Agency leaders said some stem cell companies are deceiving patients by "flouting the statutes and our regulations" and "falsely promoting their benefits."
By Kristin Jensen • April 4, 2019 -
Roche must ask Spark shareholders once again to sell
The Swiss pharma has extended its tender offer for its $4.8 billion buy of the gene therapy pioneer after failing to secure a majority of shares by a deadline.
By Jonathan Gardner • April 3, 2019 -
Sangamo hemophilia A progress boosts shares
Early data suggest Sangamo's gene replacement therapy could restore near-normal levels of a needed clotting factor. Competitors in the space still maintain a sizable lead, however.
By Ned Pagliarulo • April 2, 2019 -
AveXis buys its 4th US plant in preparation of Zolgensma launch
The six-building campus in Longmont, Colorado, gives the Swiss biotech nearly 700,000 square feet of additional space for biologic drug manufacturing.
By Jacob Bell • April 2, 2019 -
Bluebird gene therapy on cusp of European market entry
A nod from an EMA expert panel means Bluebird's LentiGlobin for beta-thalassemia has just one last hurdle before it's cleared.
By Jacob Bell • March 29, 2019 -
Q&A
Thermo Fisher's pharma head talks Brammer Bio and future M&A
Michel Lagarde, who leads Thermo Fisher's pharma services unit, explained to BioPharma Dive why the life science giant chose to enter gene therapy via a $1.7 billion deal for Brammer Bio.
By Andrew Dunn • March 28, 2019
Previous
